Success Metrics

Clinical Success Rate
93.8%

Based on 30 completed trials

Completion Rate
94%(30/32)
Active Trials
2(6%)
Results Posted
40%(12 trials)
Terminated
2(6%)

Phase Distribution

Ph not_applicable
8
24%
Ph phase_3
3
9%
Ph phase_4
5
15%
Ph phase_1
11
32%
Ph phase_2
3
9%

Phase Distribution

11

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
11(36.7%)
Phase 2Efficacy & side effects
3(10.0%)
Phase 3Large-scale testing
3(10.0%)
Phase 4Post-market surveillance
5(16.7%)
N/ANon-phased studies
8(26.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

30 of 32 finished

Non-Completion Rate

6.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

34

all time

Status Distribution
Active(2)
Completed(30)
Terminated(2)

Detailed Status

Completed30
Recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
2
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (36.7%)
Phase 23 (10.0%)
Phase 33 (10.0%)
Phase 45 (16.7%)
N/A8 (26.7%)

Trials by Status

completed3088%
recruiting26%
terminated26%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT01016834Phase 4

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Completed
NCT05211050Not Applicable

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine

Completed
NCT06503848

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Recruiting
NCT05108688Phase 4

Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache

Completed
NCT00620425Phase 1

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Completed
NCT05654298Not Applicable

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

Completed
NCT01430442Phase 2

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Completed
NCT01632657Not Applicable

Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy

Completed
NCT00892203Phase 2

Efficacy and Safety of BGG492 in the Treatment of Migraine

Completed
NCT04197349Phase 1

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

Completed
NCT04355845Phase 1

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Completed
NCT00804973Phase 2

Study in Participants With Acute Migraines Headaches

Terminated
NCT03585894Not Applicable

The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects

Completed
NCT03076970Phase 1

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Completed
NCT03310411Phase 1

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

Completed
NCT02932488Phase 1

Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Terminated
NCT02741310Phase 1

Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

Completed
NCT00701389Phase 1

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

Completed
NCT01071317Phase 4

Trial of Comprehensive Migraine Intervention

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34